



## Abstracts submitted for the APG Awards 2018

Thaksaon Kittipassorn.....	2
Kay Khine Myo Min .....	3
Debrah Renders .....	4
Aimee Horsfall.....	5
Ayla Orang.....	6
Andrew Thompson.....	7
Byron Shue .....	8
Alana Donnelly .....	9
Charlotte EJ Downes .....	10
Alexander Lewis .....	11
Stephanie Nguyen.....	12
Jia Truong.....	13
Pawanrat Tangseefa.....	14
Ellen Potoczky .....	15
Rebecca Frkic .....	16
Cameron D. Haydinger.....	18
Yu Chinn Joshua Chey .....	19
Marina Zupan.....	20
Daniel Saviane.....	21
Saira Ali .....	22
Joseph Rossi .....	23
Melissa Bennett .....	24
Erin Brazel .....	25
MD Raihan sarkar.....	26
Shaghayegh (Sherry) Dezvarei .....	27
Tom Coleman .....	28

## Thaksaon Kittipassorn

### Disruption of the glycolytic enzyme PKM2 decreases retinal Müller cell number via glucose metabolism-independent mechanism

Pyruvate kinase M2 (PKM2) is an isoform of pyruvate kinase, a cytoplasmic glycolytic enzyme. In some cancer cells, unlike its splice-variant PKM1, PKM2 is proposed to promote proliferation and drive cancer unique metabolism, termed aerobic glycolysis. PKM2 is also the only isoform found in the nucleus and shown to act as a coactivator for the transcription factor hypoxia-inducible factor-1 (HIF-1), leading to glycolysis upregulation. Furthermore, PKM2 is a target gene of HIF-1, suggesting a feedback loop between the two proteins. Surprisingly, Müller glial cells of the retina display cancer-like aerobic glycolysis. Here we examine the hypothesis that PKM2 plays a role in Müller cell proliferation and metabolism. First we verified the specificity of two PKM2 antibodies as PKM2 and PKM1 only differ in a small mutually-exclusive exon, and found that only one binds to PKM2. Using the verified antibody, we show that PKM2 is expressed in both the cytoplasm and nucleus of primary rat Müller cells and the Müller cell line rMC-1. Additionally PKM2 expression in rMC-1 cells appears to be induced in hypoxia where HIF-1 is active. PKM2 knockdown decreases rMC-1 cell number, supporting a role for PKM2 in Müller cell proliferation. Interestingly the knockdown does not significantly affect glucose metabolism in rMC-1 cells. This indicates that the role of PKM2 in Müller cell proliferation might not be mediated through glucose metabolism but may involve the HIF-1 regulatory pathway. Given this role of PKM2, its disruption might adversely affect Müller cell survival and contribute to retinal disease.

## Kay Khine Myo Min

### Desmoglein-2 as a target for tumour vasculature in melanoma

Tumour growth and cancer metastasis rely heavily on the ability of cancer cells to gain access to nutrients and oxygen, and they achieve this via angiogenesis where endothelial cells (ECs) line up to form blood vessels. We have previously discovered that the adhesion molecule desmoglein-2 (DSG2) promotes angiogenesis. Moreover, an increase in DSG2 expression has been shown to correlate with poor prognosis in cancer, especially in melanoma. Thus our aim is to determine whether DSG2 is a novel mediator of melanoma progression that can be therapeutically targeted. Our new data shows that in our syngeneic mouse model of melanoma, when a mouse melanoma cell line B16-F10 was injected into mice, tumour growth was attenuated in the desmoglein-2 loss-of-function mice (Dsg2<sup>lo/lo</sup>). An avenue that could be taken in order to counteract tumour growth is to reshape the tumour vasculature for improved infiltration of CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs). Increasing CTLs in the tumour can switch the vasculature to a high endothelial venule (HEV) phenotype, which has been reported to enable the infiltration of CTLs, and correlates strongly with reduced tumour size. Histological analyses suggest that DSG2 may actively play a role in leukocyte infiltration in melanoma, as Dsg2<sup>lo/lo</sup> mice exhibit an increase in HEVs, an increase in CD3<sup>+</sup> T lymphocytes and a decrease in FoxP3<sup>+</sup> T regulator cells involved in immune evasion. Upon inspection of CD31<sup>+</sup> vessels, Dsg2<sup>lo/lo</sup> mice also exhibited vessels with increased EC width, suggesting that DSG2 is playing a role in regulating tumour vasculature. Further work is currently underway to determine DSG2's involvement in regulating leukocyte infiltration and whether tumour vasculature can be "switched" to a high endothelial venule phenotype to promote infiltration of cancer killing T lymphocytes.

## Debrah Renders

### Nonsense Mediated mRNA Decay factors UPF3A and UPF3B have opposing roles on cell cycle in human embryonic stem cells.

Nonsense mediated mRNA decay (NMD) degrades transcripts with 5'~NMD inducing features<sup>1</sup>. UPF3A and UPF3B are gene paralogs involved in NMD. UPF3B is a strong NMD activator, while UPF3A's role is less clear, shown to have weak NMD activity and recently reported as an NMD inhibitor. Our aim was to study the role of UPF3B and UPF3A in hESCs. We used CRISPR-Cas9 genome editing technology to generate three independent knockout (KO) hESC lines each of UPF3A and UPF3B using unique gRNAs. In UPF3B clones, UPF3A protein was elevated, identifying existence of a compensatory NMD mechanism previously described in other cells. In UPF3A clones, we observed increased mRNA levels of bona fide canonical NMD targets and NMD factors consistent with impaired NMD activity. Loss of either UPF3A or UPF3B had no overt effect on hESC morphology however the expression of SOX2 and OCT3/4 were slightly reduced in the clones respectively. Cell cycle analysis revealed that UPF3B clones had an enrichment of cells in the G1 phase, whilst in opposite, UPF3A clones had reduction in the G1 phase. The expression of NMD targeted cell cycle regulatory gene CDKN2A was highly upregulated only in UPF3B clones, and may in part explain the cell cycle defect. This data demonstrates that whilst UPF3A may be dispensable for canonical NMD in hESCs, it functions in a non-redundant, opposing manner to UPF3B to control hESC cell cycling. Our results demonstrate that the persistence of this only example of NMD gene paralogs may be due to their different roles in cells.

## Aimee Horsfall

### A Fluorescent Peptide Constraint to Define Secondary Structure

Protein-protein interactions are defined by interfacial secondary structural motifs that impart a high degree of selectivity. Peptides can be designed to bind at these sites, though they are invariably unstructured, a shortcoming that can be addressed by introducing a covalent linker to define the required binding geometry. Imaging of these constrained peptides requires a fluorescent tag, however, classic constraints introduced by metathesis, lactamisation and "click" chemistry lack this property and as such it must be introduced separately. Here we repurpose a protein cross-linker, dibromobimane, as a peptide constraint to define secondary structure with intrinsic fluorescence. A series of peptides with increasing length and terminal cysteine residues were prepared by SPPS to investigate the effect of changing constraint length on the peptide backbone geometry. These peptides were then reacted with dibromobimane under biologically compatible conditions to give a new class of fluorescent peptide with defined secondary structure that can be directly imaged. All secondary structures were characterised by NMR and CD to reveal an  $i-i+2$  homocysteine-containing peptide with beta-strand structure and a single-turn helical geometry of an  $i-i+4$  constrained peptide. The fluorescent properties of the resultant constrained peptides were investigated via plate photometry and detected at concentrations as low as 10 nM, the peptides were also shown to be cell-permeable and imaged by confocal microscopy. Our new fluorescent peptide linker is introduced in an efficient manner using natural amino-acid sequences, and allows the design of new protein-protein interaction inhibitors that do not require further functionalization for in vivo studies.

## Ayla Orang

### Harnessing miRNAs to enhance the anti-cancer properties of metformin in colorectal cancer

Colorectal cancer (CRC) is the third most prevalent cancer in the world. Metformin linked to cancer prevention and selectively represses cancer progression. MicroRNAs are small non-coding RNAs involved in most cellular processes. Although several metabolic effects of metformin treatment have been investigated, detailed analysis of the resultant changes in gene expression is still required. Also, the effect of metformin treatment in combination with anti-cancer miRNAs has yet to be explored. RNA and small RNA next generation sequencing were performed for CRC cells treated with metformin. Following differential expression, functional enrichment and network analyses, CRC cells were transfected with miRNA mimics to explore the anti-cancer effect of differentially expressed (DE) miRNAs. Also, high throughput functional screens of miRNA mimics library in combination with metformin were used and secondary screen were performed to validate the hits. Protein-protein interactions and DE miRNAs and genes within specific biological pathways that are resultant from metformin treatment were identified. Also, Metformin treatment resulted in downregulation of some pro-proliferative and upregulation of some anti-proliferative miRNAs. Furthermore, miRNAs were validated to sensitize CRC cells to the anti-cancer effect of metformin by inducing its anti-proliferative effects. Identification of DE miRNAs and their potential target genes as well as miRNAs that sensitize CRC cells to metformin provides a key step towards identifying therapeutic intervention and confirms the feasibility of combining metformin with miRNAs to enhance therapeutic efficacy and overcome drug resistance. Future work includes investigation of the mechanisms of action of newly discovered miRNAs in the context of metformin.

## Andrew Thompson

### Alternate binding modes facilitate nucleoside promiscuity in MtDTBS

The rise in resistant tuberculosis (TB) infections must be combated with the development of new antibiotic therapies. The eponymous pathogen, *Mycobacterium tuberculosis* (Mt), relies on biosynthesis to generate the essential nutrient biotin, making this a promising pathway for anti-TB antibiotics. Dethiobiotin synthetase (DTBS) catalyses the penultimate step of biotin synthesis – the energy-dependant conversion of diaminopelargonic acid (DAPA) to dethiobiotin. Uniquely, MtDTBS can promiscuously utilise all nucleoside triphosphates (NTPs) for catalysis, with a preference for cytidine triphosphate (CTP). In this work, improved surface plasmon resonance (SPR) protocols aided the quantitative determination of two modes of NTP binding. The CTP-MtDTBS complex was high affinity and exhibited slow dissociation. In contrast, other ‘‘promiscuous’’ NTPs formed transient, lower affinity complexes with fast kinetics. Crystallographic studies helped define the hydrogen bonding network responsible for the high affinity binding mode, which was observed in several ligand complexed crystal structures including: cytidine-MtDTBS, cytidine diphosphate-MtDTBS, and CTP-DAPA-carbamate-MtDTBS. However, structural investigation of other NTP binding modes was prohibited by competitive binding with crystallographic precipitant molecules. To overcome this, a precipitant-ligand exchange technique was developed and 4 NTP-MtDTBS crystal structures were solved. These structures revealed that promiscuous NTPs bound exclusively to MtDTBS via the triphosphate group, a distinct mechanism from that observed for CTP. These data provide the structural basis for the promiscuous utilisation of NTPs and an unconventional mechanism of enzyme catalysis. These findings enhance our overall understanding of the MtDTBS active site and will guide the rational design of inhibitors to target this essential TB enzyme.

## Byron Shue

### Identification of RACK1 as a critical pan-flavivirus host factor for virus replication using CRISPR/Cas9 screening technology

The Flaviviruses, such as Zika virus (ZIKV), Dengue virus (DENV) and West Nile Virus are significant human pathogens that cause substantial burden on society, particularly in the developing world. Cellular factors play important roles in all facets of the flavivirus lifecycle and deciphering viral-host protein interactions is essential for understanding the flavivirus lifecycle and development of effective antiviral strategies.

To identify novel ZIKV essential host factors, we employed a CRISPR/Cas9 genome-wide KO screen approach utilising single guide RNAs (sgRNAs) targeting every gene in the human genome. sgRNAs from cells which survive the ZIKV induced cytopathic effect were PCR amplified and sequenced using Illumina NextSeq. Bioinformatics analysis identified a highly enriched cohort of sgRNA sequences representing knockout of genes critical for ZIKV replication. One host factor, RACK1 was significantly enriched across multiple screens. RACK1 plays multiple roles in homeostatic cellular processes and has been previously identified as essential for replication of several unrelated viruses (HCV, Pox virus).

siRNA knockdown of RACK1 followed by infection with ZIKV or DENV revealed that RACK1 has a critical role in replication for not only ZIKV but other members of the flavivirus family. Furthermore, RACK1 was shown via co-immunoprecipitation and proximity ligation assay to interact with numerous ZIKV non-structural proteins which are important for establishing the viral replication complex. Taken together, it is likely that RACK1 may act as a platform for the recruitment of non-structural proteins to the replication complex in the ER during early stages of flavivirus replication.





## Alana Donnelly

### Catalytically inactive dCas9 as a transcriptional roadblock to modulate gene expression

A small number of DNA-binding proteins are known to hinder the movement of an elongating RNA polymerase along DNA by acting as a physical roadblock. These roadblocking proteins make promising genome engineering tools, with applications such as loss-of-function genetic screening and construction of synthetic gene networks. Studies have shown that a catalytically inactive Cas9 enzyme (dCas9) can reduce the level of gene expression by acting as a transcriptional roadblock. This simple two-component Cas9 system and the ability to target virtually any gene, makes dCas9 a promising tool for programmable roadblocking. The effects of a number of cellular conditions, such as dCas9 concentration, promoter strength of the target gene and orientation and affinity of dCas9 binding, on dCas9 roadblocking are not yet fully understood. Through in vivo testing using simple modular systems within *E. coli* cells, we showed how increasing the promoter strength of the target gene reduces the repressive effect of dCas9, that increasing concentration of dCas9 in the cell enables greater roadblocking and that the correct orientation of dCas9 binding on the DNA is vital for effective transcription repression by dCas9. With this data, we aim to develop a mathematical model which will allow us to extract biochemical parameters describing roadblock kinetics to assist improved manipulation of gene expression through optimising roadblocking conditions.

## Charlotte EJ Downes

### Identification and computational modelling of ruxolitinib resistant mutations in JAK2-rearranged B-cell acute lymphoblastic leukaemia

JAK2 rearrangements (JAK2r) occur in approximately 5% of paediatric B-cell acute lymphoblastic leukemia (B-ALL) patients and are associated with poor prognosis. A clinical trial is currently assessing the Jak1/2 inhibitor, ruxolitinib (rux) in high-risk B-ALL cases harbouring JAK2 pathway alterations. Elucidating mechanisms of rux resistance in JAK2r B-ALL will enable the development of therapeutic strategies to overcome or avert resistance. JAK2r B-ALL was modelled in the pro-B cell line, Ba/F3, by expressing the high-risk B-ALL fusion, ATF7IP-JAK2. Rux resistance was generated following dose escalation to a clinically relevant dose of 1  $\mu\text{M}$  in three independent experiments. Sanger sequencing of RT-PCR amplified JAK2 fusion specific transcript revealed each resistant line had acquired a different mutation within the JAK2 kinase domain, suggesting that mutation-based resistance was stochastic. In addition to the identification of two known rux resistant mutations, JAK2 p.Y931C and p.L983F, a novel p.G993A mutation was also detected. Computational modelling of acquired JAK2 mutations and their influence on rux binding was performed using ICM-Pro (Molsoft L.C.C.). The mutations localised to the ATP/rux binding site of the kinase domain. JAK2 p.L983F sterically hinders rux binding, while JAK2 p.Y931C may reduce rux binding affinity by disruption of a critical hydrogen bond within the ATP-binding site. Interestingly, the novel JAK2 p.G993A mutation is predicted to alter DFG-loop dynamics by stabilising the JAK2 activation loop, potentially altering kinase activity. Understanding mechanisms of rux resistance, as modelled here, has the potential to inform future drug design in this high-risk patient cohort.

## Alexander Lewis

### Dual sphingosine kinase and Bcl-2 inhibition exhibits synergistic cell death in acute myeloid leukemia

Pro-survival Bcl-2 family proteins such as Mcl-1 and Bcl-2 have garnered significant interest as therapeutic targets due to their up-regulation in many cancers, including acute myeloid leukaemia (AML), leading to enhanced cancer cell survival. Small molecule inhibitors such as the selective Bcl-2 inhibitor, Venetoclax, are very effective in some cancers that are highly dependent on Bcl-2, but have demonstrated poor single agent efficacy in AML due to these cells being highly dependent on Mcl-1. Sphingosine kinase 1 (SK1) is a signalling enzyme with established roles in oncogenesis and has recently emerged as a potential therapeutic target in leukaemia. We recently demonstrated that the selective SK1 inhibitor, MP-A08 exhibits anti-leukemic activity in vitro and in vivo using patient derived AML xenograft models. MP-A08-mediated cytotoxicity in AML cells correlated with a reduction in Mcl-1 levels, as well as upregulation of BH3 only proteins. Here, we found that combination therapies with MP-A08 and Venetoclax induced synergistic cell death in AML cell lines and patient samples. Mechanistically, MP-A08 induces transcriptional upregulation of BH3 only protein, Noxa and formation of Noxa/Mcl-1 complexes. MP-A08 appears to exert its cytotoxicity in AML cells through loss of Mcl-1 as a consequence of Noxa binding. Combining MP-A08 and Venetoclax significantly reduced leukemic burden in a patient derived AML xenograft model. This data provides pre-clinical evidence to investigate dual MP-A08 and Venetoclax as a potential therapeutic strategy in AML.



## Stephanie Nguyen

### Structural insights into the essential *Aspergillus fumigatus* enzyme, nucleoside diphosphate kinase.

Invasive aspergillosis is a serious infection commonly occurring in immunocompromised patients and is often caused by the fungus, *Aspergillus fumigatus*. The increasing resistance to currently available antifungal therapies and the high mortality rate of invasive aspergillosis highlights the need to characterise novel antifungal targets in *A. fumigatus*. Previously demonstrated to be essential for viability in *A. fumigatus*, nucleoside diphosphate kinase (NDK) is vital in maintaining the nucleotide triphosphate pool for DNA synthesis and therefore poses as an attractive antifungal drug target. Two atomic structures of this novel antifungal target were solved using X-ray crystallography, revealing a hexameric arrangement of the enzyme as a stack of two trimers. Comparison between the *A. fumigatus* NDK structure in apo state (2.0 Å...) and bound to both ADP and magnesium (2.2 Å...) reveals the movement of a loop containing residue Phe59 that forms a pi-pi stacking interaction with the adenine of ADP to position the product in the active site. This study provides a structural foundation for rational drug design of inhibitors of NDK. Future work is planned to involve co-crystallisation of NDK with other nucleotide triphosphates and diphosphates, ATP analogues and known inhibitors to obtain a more comprehensive understanding of the binding mechanism.

## Jia Truong

### Crystal structures of an unusual transcriptional activator from bacteriophage 186

The temperate coliphage 186, after infecting its host bacterium *Escherichia coli*, can follow either the lytic or the lysogenic developmental pathways. Crucial to this developmental decision is the lysogeny promoting factor CII. This potent transcriptional activator activates the early lysogenic promoter pE at least 400 fold, to build up sufficient immunity repressor levels for a portion of infections to commit to lysogeny. Its potency and its unusual property of binding to half sites separated by 20 base pairs, center-to-center, suggests it may activate the pE promoter by a novel mechanism. Three crystal structures of the CII protein were solved to 2-3 Å. The structures reveal that a tetrameric arrangement of CII is necessary for DNA binding, which was subsequently validated by mutational analysis and native mass spectrometry. CII is degraded *in vivo* into a specific transcriptionally inactive product. The crystal structures explain the altered self-association of the degradation product and its loss of activity. The structures combined with mutagenesis data provide a basis for modelling the CII-RNA polymerase complex at the promoter to aid in understanding the promoter activation mechanism.

## Pawanrat Tangseefa

### Metabolic and reproductive abnormalities in mice with impaired skeletal-mTORC1 function mirror a dietary restriction phenotype

Dietary restriction (DR) improves whole-body metabolism, and reduces reproductive function. While the mechanisms leading to these profound physiological changes remain to be elucidated, suppression of mTORC1 is thought to play a critical role. The skeleton has recently emerged as a critical endocrine tissue that regulates glucose and energy metabolism and male reproductive function, via release of the bone-specific hormone osteocalcin (OCN), suggesting that suppression of mTORC1 in the skeleton could play a crucial role in the physiological responses to DR. To investigate the role of skeletal-mTORC1 in modulating glucose metabolism and male fertility, we generated mice in which raptor, an essential component of mTORC1, is specifically deleted in osteoblasts (Raptor<sup>OB</sup><sup>-/-</sup>). Raptor<sup>OB</sup><sup>-/-</sup> mice are significantly smaller than controls, have increased bone marrow adipose tissue (MAT) and reduced serum OCN levels. Compared to controls, serum adiponectin levels are significantly elevated in Raptor<sup>OB</sup><sup>-/-</sup> animals, while leptin levels are reduced. Importantly, despite being hypoinsulinemic, Raptor<sup>OB</sup><sup>-/-</sup> mice have significantly lower fasting glucose levels, suggestive of insulin hypersensitivity. Consistent with this, insulin and glucose tolerance tests have revealed that Raptor<sup>OB</sup><sup>-/-</sup> mice have improved glucose tolerance, enhanced insulin sensitivity and elevated insulin secretion. Furthermore, the reproductive function of male Raptor<sup>OB</sup><sup>-/-</sup> mice is significantly impaired, as evidenced by reduced circulating testosterone levels and sperm counts. Collectively, our results demonstrate that physiological changes associated with DR (e.g. elevated MAT and circulating adiponectin levels, reduced leptin levels, improved glucose metabolism and low testosterone levels) are mirrored in Raptor<sup>OB</sup><sup>-/-</sup> mice, which suggests that skeletal mTORC1 signalling is critical in mediating cellular responses to DR.

## Ellen Potoczky

### PR/Set domain 5: A Critical Transcriptional Regulator of Craniofacial Development

Development of the craniofacial skeleton is dependent on complex cellular processes involving cellular migration, differentiation and morphogenesis. Disruption of these processes can result in craniofacial defects which have a significant impact on quality of life. To identify the genes and molecular pathways involved in craniofacial development, an N-ethyl-N-nitrosourea mutagenesis forward genetic screen was performed in zebrafish. From this screen, a novel zebrafish line with craniofacial defects was discovered, which contained a mutation in the PRDM5 gene. Interestingly, PRDM5 mutations have been identified in humans with Brittle Cornea syndrome, where patients exhibit corneal thinning and severe corneal ruptures with associated hearing loss. Alcian blue staining of this unique zebrafish line revealed chondrocyte stacking defects and a morphogenic change in Meckel's and palatoquadrate cartilage of the lower jaw. As chondrocytes are a Neural Crest derivative, these cartilage defects suggest a role for PRDM5 in Neural Crest cell development. Comparative expression analysis revealed no significant changes in Neural Crest induction and migration, however a reduction in Collagen Type 2 alpha1 (Col2a1) was identified in homozygous mutants, suggesting that PRDM5 normally acts as a positive regulator of Col2a1 expression in cartilage precursors. Given the homology between the proximal portion of Meckel's cartilage and the palatoquadrate cartilage of zebrafish with the incus and malleus of the middle ear in mammals, this data provides new insight into the mechanisms by which PRDM5 mutations contribute to the etiology of Brittle Cornea syndrome.

## Rebecca Frkic

### Optimisation of PPAR $\alpha$ Partial Agonists for Improved T2DM Therapies

Peroxisome Proliferator-Activated Receptor  $\alpha$  (PPAR $\alpha$ ) is a ligand-activated nuclear receptor which plays a key role in fatty acid and glucose homeostasis. PPAR $\alpha$  is the molecular target for type 2 diabetes mellitus (T2DM) therapeutics known as the TZDs (thiazolidinediones), drugs that offer robust clinical benefit in terms of normalising fasting glucose. However, the TZDs, which are full agonists of the receptor, have been confounded with significant side effects. In recent years, it has been shown that partial agonists of PPAR $\alpha$  have displayed similar insulin sensitising efficacy as the full agonist TZDs, but lack many of the undesirable side effects of the full agonists. One such partial agonist, INT131, has shown potent insulin-sensitising actions with reduced side effects as compared to the TZDs. To probe the structure-activity relationship (SAR) of the INT131 scaffold, 14 analogues of INT131 were synthesised. SAR studies of the analogues revealed compounds with higher transcriptional potency for PPAR $\alpha$  as well as identification of moieties of the INT131 scaffold key to high transcriptional potency. The sulphonamide linker is absolutely critical to activity, substitutions at position 4 of the benzene ring A were associated with higher transcriptional activity, substitutions at position 2 of benzene ring A aided in tighter packing and activity, and the ring type and size of ring A was correlated to the degree of activity.





Ruby Dawson

### A conditional mouse model of GATOR1-related focal epilepsy supports a second-hit mechanism of disease

Heterozygous mutations in DEPDC5, NPRL2 and NPRL3, which encode the GATOR1 complex, have been found in families with focal epilepsy. However the pathological mechanism of how these mutations cause the disease remains elusive. GATOR1 functions to inhibit mTOR signalling and hyperactivity of this pathway has independently been linked with epilepsy. Therefore, mTOR pathway deregulation is hypothesised to be the major factor in the pathology of GATOR1-related epilepsy.

We developed a functional assay using CRISPR null cell lines, where mutations are screened based on their ability to rescue the null phenotype of hyperactive mTOR. Several mutations have been confirmed to have lost this function, supporting a link between mTOR deregulation and the disease. Interestingly, many of the missense mutations screened retained their function, highlighting that some predicted disease-causing mutations may not be pathogenic.

We aimed to further investigate the disease pathology using a mouse model. Following our initial finding that *Depdc5* heterozygous mice do not display any human disease phenotypes, we are now investigating a 'second-hit' mechanism of disease. This is where seizures are proposed to result from a second, somatic mutation in the brains of germline heterozygotes, resulting in null cell clones. This mechanism is supported by the variable foci, incomplete penetrance of the disease and the finding of a somatic mutation in DEPDC5 in one patient.

We therefore established a conditional mouse for *Depdc5* to model this mechanism.

Using CRISPR, we generated a floxed allele which, following the unilateral electroporation of Cre into developing brains, recombines to result in discrete regions of null tissue. We observed increased mTOR signalling and increased soma size in DEPDC5 null neurons. We are performing seizure threshold testing to determine if these molecular changes translate to disease phenotypes. Data from mutant cell line and mouse investigations support the involvement of mTOR deregulation in GATOR1-related epilepsy and a second-hit disease mechanism.

## Cameron D. Haydinger

### Molecular drivers of aerobic glycolysis in the mammalian retina

Most glucose metabolised by the mammalian retina is converted to lactate after glycolysis despite the availability of adequate oxygen for complete breakdown by oxidative phosphorylation. This type of metabolism, known as aerobic glycolysis or the Warburg effect, is common in highly proliferating cells including cancer cells, but rare in non-proliferating tissues such as the retina. Several pathways are known to drive aerobic glycolysis in cancers, but those that drive it in the retina are unknown. To elucidate drivers in the retina, we treated cultured immortalised Müller cells, a type of retinal glial cell that displays aerobic glycolysis, with inhibitors of proteins known to drive the process in cancers. Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were measured using an extracellular flux analyser, informing lactate production and oxidative phosphorylation rates, respectively. When treated with an inhibitor of a small GTPase, Rac1, Müller cells had a dramatically reduced ECAR without a simultaneous decrease in OCR, indicating that Rac1 drives aerobic glycolysis in these cells. A partial decrease in lactate production was also observed when Müller cells were treated with PI3K inhibitors in the presence of serum, and this effect was independent of PI3K's canonical downstream signal mediator Akt. We are currently exploring the role of Rac and related signalling pathways in vivo. Dysregulated glucose metabolism is a possible cause of blinding diseases such as diabetic retinopathy. By understanding the protein pathways that drive aerobic glycolysis in the retina, we may be able to unravel specific causes of disease and develop new targeted treatments.

## Yu Chinn Joshua Chey

### Sn'HIF<sup>±</sup>ing out HIF in Multiple Myeloma

Multiple myeloma (MM) is a plasma cell (PC) dyscrasia characterised by the abnormal proliferation and dissemination of PCs throughout the skeleton. As the bone marrow microenvironment is well-established to be hypoxic, hypoxia is thought to promote tumour growth, angiogenesis, metastasis and bone osteolysis. Major cellular transcriptional changes in response to hypoxia are mediated through the heterodimeric Hypoxia-Inducible Factors (HIFs). The two main isoforms of the oxygen-regulated HIF alpha subunit, HIF-1<sup>±</sup> and HIF-2<sup>±</sup>, mediate both overlapping and disparate responses in a tumour-specific context. While the HIFs have been implicated in the progression of MM, their distinct roles have not been well elucidated. To explore each HIF<sup>±</sup> isoform's role in the context of MM, we used CRISPR/Cas9 technology to develop both doxycycline (dox)-inducible and constitutively knocked-out monoclonal MM cells for both HIF1<sup>±</sup> and HIF2<sup>±</sup> in 5TGM1 murine MM cells. Using a modified lentivirus gRNA plasmid with an mPlum selection marker, we have successfully generated inducible HIF<sup>±</sup> knock-out cells at a high transduction efficiency. Induction of CRISPR/Cas9 activity occurs specifically on dox-treatment and constitutively knocked-out monoclonal MM lines were sequence verified by sanger sequencing. Ultimately, we aim to use pooled monoclonal MM cells to study the effects of each HIF<sup>±</sup> knockout on MM disease progression and dissemination in the syngeneic KaLwRij mouse model. Extending our limited understanding of HIF<sup>±</sup> roles in MM will help build the rationale for targeting the hypoxic BM niche and for the repurposing of HIF inhibitors in MM therapy.

## Marina Zupan

### Elucidating the Zn(II)-binding mechanism of the pneumococcal protein AdcAll.

*Streptococcus pneumoniae* is a globally significant human pathogen responsible for 1–2 million deaths annually. To colonise and persist within the host, the bacterium must acquire the transition metal ion zinc [Zn(II)], present at low concentrations in the host environment. In *S. pneumoniae*, Zn(II) import is facilitated by the ATP-binding cassette transporter, AdcCB, and two Zn(II)-specific solute binding proteins, AdcA and AdcAll. While AdcA and AdcAll both deliver Zn(II) to the AdcCB transporter, AdcAll has a more critical role for survival under Zn(II) starvation. Although its importance to Zn(II) acquisition is well-characterised, the molecular details of how the protein selectively acquires Zn(II) remain poorly understood. Structural information is currently available for Zn(II)-bound AdcAll, however, our understanding of the Zn(II)-binding mechanism of the protein is limited by the lack of an open, metal-free crystal structure. In this study, we overcame this issue by mutating each of the Zn(II)-coordinating residues of AdcAll and performing structural and biochemical analyses. Structural analyses of the Zn(II)-bound AdcAll variant isoforms revealed how specific regions within the protein undergo conformational changes via their direct coupling to each of the metal-binding residues. Complementing this work, metal-binding studies revealed that mutagenesis of the coordinating residues altered both the metal ion selectivity of the protein and its affinity for Zn(II). Collectively, these results provide new insight into the mechanism of Zn(II)-binding by AdcAll and the biophysical basis by which the protein confers selectivity for this essential metal ion.

## Daniel Saviane

### Elucidating the importance of alpha-macroglobulin dimers in innate immunity

Alpha-macroglobulins ( $\hat{\alpha}$ M) are a highly conserved family of secreted proteins. The predominant  $\hat{\alpha}$ M family member in humans is alpha-2-macroglobulin ( $\hat{\alpha}2$ M), which is best known as a protease inhibitor, but can also stabilise misfolded proteins, facilitate the clearance of bacteria and influence many signalling pathways. Native  $\hat{\alpha}2$ M is a tetramer, but is induced to dissociate into dimers by hypochlorite, an oxidant generated during inflammation. Additionally, during pregnancy and inflammation, pregnancy zone protein (PZP), which shares ~70% amino acid sequence identity with  $\hat{\alpha}2$ M, is markedly upregulated. Compared to what is known about the native  $\hat{\alpha}2$ M tetramer, far less is known about the biological importance of dimeric  $\hat{\alpha}$ M. The overarching goal of this project is to characterise the functions of  $\hat{\alpha}2$ M dimers, including those generated using drug-like small molecules. Preliminary studies show that (i)  $\hat{\alpha}2$ M dimers are generated by FDA-approved n-acetyl cysteine and (ii) compared to the native  $\hat{\alpha}2$ M tetramer, hypochlorite-modified  $\hat{\alpha}2$ M dimers preferentially bind to the surface of group A Streptococcus bacteria. A better understanding of the functions of  $\hat{\alpha}2$ M dimers will help us to determine whether or not increasing their levels will have therapeutic benefits in infectious diseases and beyond.

## Saira Ali

### Long non-coding RNA-protein interactions and butyrate sensitization of colorectal cancer cells

Colorectal cancer (CRC) is the second most common cause of Australian cancer related deaths. The development of CRC is associated with epigenetic alterations including altered histone acetylation patterns and dysregulated long non-coding RNA (lncRNA) expression. Butyrate, a short-chain fatty acid, produced from the fermentation of dietary fibre in our gut, has been shown to alter CRC cell behaviour through epigenetic mechanisms. Butyrate can alter CRC gene expression, including lncRNA expression, via histone deacetylase inhibition activity, resulting in decreased proliferation and increased apoptosis. lncRNAs regulate gene expression through various mechanisms including epigenetic modifications, lncRNA-miRNA, lncRNA-mRNA, lncRNA-protein interactions and their ability to produce regulatory ncRNAs, such as miRNAs. lncRNAs have been shown to regulate cell growth and apoptotic pathways in CRC. The effect of exposing CRC cells to the anti-tumorigenic molecule, butyrate, in combination with lncRNA knockdown has yet to be investigated. High throughput functional screens were used to systematically identify oncogenic lncRNAs, which when knocked down resulted in the sensitization of CRC cells to butyrate (enhanced anti-proliferative and pro-apoptotic effects). Knockdown of some lncRNAs resulted in enhanced apoptosis in the presence of butyrate. Pathway and network analyses assisted in identification of predicted key lncRNA-protein interactions involved in apoptosis. Further investigation of lncRNA knockdown and their protein interactors in the context of butyrate is required. Identification of oncogenic lncRNAs, and protein interactors, with the ability to sensitise CRC cells to butyrate when suppressed, may reveal the potential chemo-preventive or therapeutic value of these biological molecules.



## Joseph Rossi

### Utilising a Tri-Partite Split GFP Assay to Characterise Novel Protein-Protein Interactions

The basic Helix-Loop-Helix PER-ARNT-SiM (bHLH-PAS) transcriptionfactor Single Minded 1 (SIM1) is integral to hypothalamic development, and through maintained expression within these neurons regulatessatiety. Orthopedia (OTP) is a homeodomain containing transcriptionfactor which is expressed in similar regions of the hypothalamus toSIM1 and has an analogous role in hypothalamic development and satiety. Importantly, mutations in both factors have been linked to hyperphagic obesity in human patients. We have recently demonstrated by immunohistochemistry that SIM1 and OTP are indeed expressed in the same neurons of the hypothalamus. Through co-immunoprecipitation (Co-IP) experiments, we then identified the existence of a SIM1/OTP complex. Additional Co-IP experiments have started to elucidate the domains of interaction between SIM1 and OTP. To further characterise the novel interaction, we have employed the Tri-partite Split GFP system developed by Cabantous et. al. (DOI: 10.1038/srep02854). In this system the two proteins of interest are each uniquely tagged with a small GFP fragment. The remainder of the GFP protein not included in the tags forms a third fragment. If the two proteins interact, the small GFP tags will form a complex capable of interacting with the large GFP fragment, forming a complete GFP molecule capable of producing green fluorescence. Preliminary data for the Tri-partite Split GFP assay has confirmed the interaction between SIM1 and OTP, as well as providing information on the likely cellular localisation of the interaction. We have started to characterise a novel interaction between SIM1 and OTP that may have implications in appetite control and obesity.

## Melissa Bennett

### Inhibition of glucosylceramide synthase causes multiple myeloma cell death alone and in synergy with bortezomib via enhanced endoplasmicreticulum stress

Ceramide is an apoptotic sphingolipid which is often elevated in cells by chemotherapy and radiotherapy, and contributes to the cell death caused by these agents. Some cancers are able to avoid the pro-apoptotic signalling produced by ceramide by upregulating enzymes which are able to convert ceramide to less apoptotic sphingolipids. Glucosylceramide synthase (GCS), which converts ceramide to glucosylceramide, is one such enzyme. One cancer in which GCS seems to be important is multiple myeloma, a currently incurable blood cancer which arises from plasma cells. GCS is significantly upregulated in patient myeloma cells compared to normal plasma cells. Inhibition of GCS, both genetically through shRNA, and pharmacologically through the GCS inhibitor PDMP, causes cell death of myeloma cell lines, as measured by flow cytometry with Annexin-V/PI staining. This cell death was accompanied by an increase in markers of endoplasmic reticulum (ER) stress and caspase-3 cleavage, suggesting the mechanism of cell death is apoptosis induced by enhanced ER stress. Furthermore, combining PDMP with the proteasome inhibitor bortezomib, which is current first line therapy for MM, is able to cause synergistic cell death of MM cell lines, even in cell lines that are bortezomib resistant, with was associated with synergistic induction of ER stress. Given that bortezomib resistance is a substantial hurdle in the treatment of MM, the ability of PDMP to improve bortezomib response in these cells is highly significant. Therefore, it seems that GCS inhibition may be a viable target in multiple myeloma.



## Erin Brazel

### Overcoming antimicrobial resistance – exploiting zinc intoxication to restore antibiotic efficacy

The prevalence of antibiotic resistant pathogens continues to rise and threatens to disrupt healthcare on a global scale. To combat antibiotic resistance, novel strategies for treating bacterial infections are urgently required. The metal ion zinc has a critical role in innate immune defense and its deficiency is associated with a marked increase in susceptibility to bacterial infections. *Streptococcus pneumoniae* is a major cause of local and invasive diseases and is associated with significant human mortality. Despite the importance of zinc at the host-pathogen interface, the impact of zinc stress on *S. pneumoniae* remains poorly understood. Here, we investigated how zinc stress affected the virulent *S. pneumoniae* D39 strain using a combination of phenotypic growth, cellular metal accumulation and macrophage survival analyses. These studies revealed that *S. pneumoniae* encoded a cation diffusion facilitator family transporter (CzcD) that was capable of zinc efflux and contributed to pneumococcal survival within phagocytic cells. We further examined the impact of zinc stress by abolishing *czcD* functionality. This revealed that zinc intoxication rendered *S. pneumoniae* more sensitive to specific classes of antibiotics. Building on these findings, we examined synergism between zinc and antibiotics using ionophores to increase the potency of zinc stress. Ionophore-mediated zinc treatment restored antibiotic susceptibility to the multidrug resistant *S. pneumoniae* 23F strain. Collectively, this study provides detailed insight into zinc resistance in *S. pneumoniae* and highlights the therapeutic potential of zinc and ionophores as adjuvants to antibiotics as a novel treatment strategy.

## MD Raihan sarkar

The investigation of new monooxygenase enzymes as biocatalyst for selective C-H bond oxidation reactions

The cytochrome P450 enzyme CYP101B1 from the bacterium *Novosphingobium aromaticivorans* DSM12444 binds and oxidises norisoprenoids and other structurally diverse classes of substrate. CYP101B1 catalyses the oxidation of norisoprenoids such as  $\beta$ -ionone with high activity and coupling efficiency. Substrate engineering using acetate, isobutyrate, amide directing groups with the aim of mimicking the butenone sidechain of the norisoprenoids was undertaken with cyclic alcohol and terpenes. This approach significantly increased the affinity, activity and coupling efficiency of CYP101B1 for the esters/amides compared to the parent alcohol or amine. The majority of the turnovers were regio- and stereo-selective for C-H bond hydroxylation. CYP101B1 is also able to bind and oxidise aromatic substrates but at a lower activity and efficiency than norisoprenoids and monoterpene esters described above. Based on protein sequence alignments we hypothesised the sidechain of histidine 85 would interact with the carbonyl groups of the favoured norisoprenoid substrates of CYP101B1. Site directed mutagenesis of residue histidine 85 of CYP101B1 to phenylalanine (F) was used with the aim of improving the activity of the enzyme for more hydrophobic substrates. The H85F variant of CYP101B1 showed enhanced affinity and activity towards alkylbenzenes, styrenes and methyl naphthalenes. Finally the affinity and activity of CYP101B1 for a series of 4-methyl cubane derivative was also determined. These substrates would be held in the substrate binding pocket of CYP101B1 in such a fashion that the methyl (or ethyl) C-H bonds would be close to the heme iron enabling efficient and selective abstraction to occur at this position. The oxidation of cubane at this position would enable an assessment of the nature of any carbon based radical intermediate formed during this process and allow us to probe the mechanism of this important family of enzymes.

## Shaghayegh (Sherry) Dezvarei

### Conversion of a versatile monooxygenase into a peroxygenase by a single mutation

The cytochrome P450 family of monooxygenase enzymes oxidise unreactive C-H bonds, by activating molecular dioxygen to form a reactive iron-oxo intermediate. CYP102A1 from *Bacillus megaterium* (P450Bm3) is one of the most utilized P450 enzymes in biocatalytic hydroxylation studies because of its high solubility and activity. Moreover, the fusion of reductase and heme domain makes it a self-sufficient enzyme which just needs NADPH cofactor as a source of electrons. A mutant variant of CYP102A1, R19 (R47L/Y51F/H171L/Q307H/N319Y) was generated which shifts the substrate range away from fatty acids, which are oxidised by the wild-type enzyme, to range of other substrates. The activity of this variant was tested with styrene, ethylbenzene and thioanisole and an enhancement of 100-, 50- and 3-fold, respectively, compared to the WT enzyme was found. The activity was further improved by the co-addition of fluorinated fatty acid like decoy molecules but the selectivity of the enzyme was maintained. One of the drawbacks of using these monooxygenase enzymes as biocatalysts is the high cost of NADPH, which limits their application. Inspired by CYP152A1, a natural H<sub>2</sub>O<sub>2</sub>-dependent peroxygenase enzyme, a single mutation of threonine 268, which is involved in dioxygen activation, to glutamic acid was made to haem domain of CYP102A1. This mutant was found to convert the enzyme into a hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) dependent variant. This variant displayed oxidation of the aforementioned substrates with H<sub>2</sub>O<sub>2</sub>. The addition of decoy molecules did not improve activity, with the T268E peroxygenase but was found to alter the stereo-selectivity of ethylbenzene oxidation.

## Tom Coleman

Structural investigation of the role of the substrate and the acid-alcohol pair of residues in dioxygen activation by cytochrome P450 enzymes; with insight into the active oxidant(s) employed by CYP199A4.

The ubiquitous cytochrome P450 superfamily of enzymes catalyse the insertion of an oxygen atom into usually unreactive C-H bonds. These enzymes are critical for mammalian xenobiotic metabolism, as well as natural product biosyntheses. These enzymes use molecular dioxygen which is activated to form the reactive intermediate, Compound I (CpdI;  $\text{PorFeIV=O}$ ) [1]. The details of oxygen activation are based predominantly on structural work from a single enzyme, P450cam (CYP101A1). Mutation of the highly conserved pair of acid-alcohol residues, Asp251 and Thr252, suggested that the threonine plays a role in stabilising the iron-oxy intermediate, while the aspartate is thought to facilitate delivery of protons to the active site [2].

Here we use the bacterial CYP199A4 P450 enzyme, from the metabolically diverse *Rhodospirillum rubrum* HaA2, to shed further insight into the mechanism of oxygen activation and substrate oxidation by P450 enzymes. CYP199A4 catalyses the regioselective oxidation of para-substituted benzoic acid substrates. It can accept a wide variety of functional groups and perform a wide variety of oxidations, such as hydroxylation, oxygen/nitrogen dealkylation, desaturation, and sulfuroxidation.

Crystal structures of CYP199A4 were solved, in which the equivalent acid-alcohol pair of residues were mutated. These indicated that CYP199A4 is less sensitive to mutation induced structural changes than P450cam. In addition, turnover studies were performed which revealed unexpected high levels of product formation for these mutants. These results prompt further discussion on whether the mechanistic details of P450cam can be extrapolated to other systems.

### References

[1] Rittle, J., Green, M.T., 2010, *Science*, 330, 3006, 933-937. [2] Sligar, S., Denisov, I., In *Cytochrome P450: Structure, Mechanism, and Biochemistry*, 4th ed.; Ortiz de Montellano, P., Ed.; Springer: New York, 2015; Chapter 3.